New York 2025 Session Status: Introduced

A2126 — Establishes a pilot program on upper payment limits for prescription drugs

Last action — In Assembly Committee

  1. 1
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Assembly
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill has been introduced in the Assembly. Introduced January 15, 2025. It must pass committee before a floor vote.

Next likely step: a committee referral and hearing.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Not enough signal yet

Not enough signal yet to read this bill's trajectory — we surface a likelihood only once there's real movement (stage, sponsorship, committee, or votes) to point to.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

In plain language

Establishes a pilot program to set upper payment limits for prescription drugs.

This bill creates a pilot program that sets upper payment limits for prescription drugs, not lower than the maximum fair price determined by federal authorities. The specific details of the program are not available as the bill text is not provided.

Summary

Establishes a pilot program on upper payment limits for prescription drugs; provides that an upper payment limit shall not be less than the maximum fair price for a drug published by the secretary of the US department of health and human services.

Bill Text

Action History

  1. PRINT NUMBER 2126B

  2. AMEND (T) AND RECOMMIT TO INSURANCE

  3. PRINT NUMBER 2126A

  4. AMEND AND RECOMMIT TO INSURANCE

  5. REFERRED TO INSURANCE

  6. REFERRED TO INSURANCE

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 218 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (218)

218 members have not signed on to this bill.

Show all 218 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does A2126 do?
Establishes a pilot program on upper payment limits for prescription drugs; provides that an upper payment limit shall not be less than the maximum fair price for a drug published by the secretary of the US department of health and human services.
Who sponsors A2126?
A2126 is sponsored by Sarahana Shrestha.
What is the current status of A2126?
This bill has been introduced in the Assembly. Introduced January 15, 2025. It must pass committee before a floor vote.
Where can I track A2126?
Track A2126 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on A2126

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of A2126

Last checked for changes 5 days ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →